Lab Capacity and Environmental Surveillance Expanded to Combat Antimicrobial Resistance in India

India has expanded its laboratory capacity and linked environmental surveillance platforms to address the growing threat of antimicrobial resistance (AMR) in the country, announced Anupriya Patel, Union Minister of State for Health and Family Welfare, at the AMR NEXT 2025 conclave held at Amrita Hospital, Faridabad, November 29, 2025. This expansion is part of a broader National Action Plan aligned with the One Health approach, uniting human, animal, and environmental health systems to detect trends and respond more effectively to AMR threats.​

Key Developments in India’s AMR Strategy

The laboratory enhancements include the standardization of testing methods and expanded capacity to track resistant pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii. Recent data from the Indian Council of Medical Research (ICMR) show a slight increase in E. coli susceptibility to ceftazidime from 19.2% in 2023 to 27.5% in 2024, yet rising resistance to carbapenems and colistin remains a critical concern, indicating dwindling treatment options. The integration of surveillance data across sectors also aids India’s contribution to global AMR monitoring with the World Health Organization.​

Expert Perspectives and Public Health Context

Dr. Sanjeev Singh, Medical Director at Amrita Hospital, highlighted AMR’s severe implications on health systems, including increased mortality, extended hospital stays, and escalating healthcare costs. Professor Alison Holmes OBE from Imperial College London emphasized the need for a strengthened, coordinated international effort to combat AMR effectively. India ranks among countries with the highest bacterial infection burdens, confronting key drivers like high infectious disease load, misuse of antibiotics in humans and animals, easy over-the-counter antibiotic access, and environmental contamination from pharmaceutical waste.​

Implications for Public Health and Daily Life

Antimicrobial resistance threatens decades of medical progress by limiting effective treatments for common infections, making routine surgeries and therapies riskier. For individuals, this means infections may take longer to cure and could require more expensive or toxic treatment regimens. The expansion of lab and surveillance infrastructure supports earlier detection and targeted interventions, which can help preserve antibiotic efficacy and manage infection risks in communities.​

Limitations and Challenges

While India’s expanded surveillance and laboratory capacity mark critical progress, challenges remain including the need for robust regulatory frameworks, public awareness, and diagnostic stewardship. Resistance patterns continue to evolve, and efforts must be sustained with political commitment and international cooperation. Addressing environmental contributors to AMR, such as hospital effluent contamination, also remains a vital priority.​

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References:​